BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 3031173)

  • 1. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
    Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
    J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy.
    Stanberry LR; Harrison CJ; Bernstein DI; Burke RL; Shukla R; Ott G; Myers MG
    Antiviral Res; 1989; 11(4):203-14. PubMed ID: 2545166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
    J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
    Stanberry LR; Burke R; Myers MG
    J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
    JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine.
    Thornton B; Baskerville A; Bailey NE; Melling JM; Hambleton P
    Vaccine; 1984 Jun; 2(2):141-8. PubMed ID: 6099646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs.
    Zhang P; Xie L; Balliet JW; Casimiro DR; Yao F
    PLoS One; 2014; 9(6):e101373. PubMed ID: 24979708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].
    Brans R
    Hautarzt; 2010 Dec; 61(12):1073-8. PubMed ID: 21052616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.